Search

Displaying results 1671 - 1680 of 6835 in total
  1. Drug

    Quercus stellata pollen

    go.drugbank.com/drugs/DB10888
    Approved

    Quercus stellata pollen is the pollen of the Quercus stellata plant. Quercus stellata pollen is mainly used in allergenic testing.

    Mixtures: 5-oak Mix, Blackjack/bur/post/red/white Pollen
  2. Drug

    Oxymorphone

    go.drugbank.com/drugs/DB01192
    ApprovedVet approved

    On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. … It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092).

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Orphenadrine

    go.drugbank.com/drugs/DB01173
    ApprovedInvestigational

    A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

    Mixtures: MYOGESIC-OCategories: Ethers, Chemically Close to Antihistamines
  4. Drug

    Ramipril

    go.drugbank.com/drugs/DB00178
    ApprovedInvestigational

    Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. … Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).

  5. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]

  6. Drug

    Clofazimine

    go.drugbank.com/drugs/DB00845
    ApprovedInvestigationalWithdrawn

    [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis

  7. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    and resolve within 2 to 3 weeks. … TrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

  8. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other

  9. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … [L44361,L44366] Adagrasib joins [sotorasib] as another KRAS<sup>G12C</sup> inhibitor approved by the FDA.[A254062]

  10. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. … It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival